Provided by Tiger Trade Technology Pte. Ltd.

Amphastar Pharmaceuticals

28.57
-0.0400-0.14%
Post-market: 28.570.00000.00%16:20 EST
Volume:182.57K
Turnover:5.23M
Market Cap:1.31B
PE:12.59
High:28.92
Open:28.75
Low:28.49
Close:28.61
52wk High:32.69
52wk Low:20.39
Shares:45.95M
Float Shares:34.80M
Volume Ratio:0.51
T/O Rate:0.52%
Dividend:- -
Dividend Rate:- -
EPS(TTM):2.27
EPS(LYR):3.06
ROE:14.84%
ROA:6.74%
PB:1.69
PE(LYR):9.34

Loading ...

Is Amphastar (AMPH) Turning Margin Compression Into a Test of Its Operational Discipline?

Simply Wall St.
·
Feb 06

Amphastar Pharmaceuticals (AMPH) Gets a Hold from Bank of America Securities

TIPRANKS
·
Jan 20

A Look At Amphastar Pharmaceuticals (AMPH) Valuation After The AMP-110 License Agreement With Nanjing Hanxin

Simply Wall St.
·
Jan 16

Amphastar Pharmaceuticals Showcases Pipeline Shift to Proprietary and Biosimilar Products in New Presentation

Reuters
·
Jan 13

Amphastar Pharmaceuticals: Made $2 Mln Upfront Payment to Hanxin Upon Signing

THOMSON REUTERS
·
Jan 12

Amphastar Pharmaceuticals: Additional Payments to Hanxin of up to $14 Mln in Development Milestone Payments, up to $75 Mln in Sales Milestone Payments

THOMSON REUTERS
·
Jan 12

Amphastar Pharmaceuticals: License Agreement With Nanjing Hanxin Pharmaceutical Technology for Fully Synthetic Corticotropin Compound

THOMSON REUTERS
·
Jan 12

Amphastar Pharmaceuticals Signs Exclusive License Agreement for Synthetic ACTH Compound

Reuters
·
Jan 12

Assessing Amphastar Pharmaceuticals (AMPH) Valuation After Recent Share Price Momentum

Simply Wall St.
·
Jan 08

BofA Securities Adjusts Price Target on Amphastar Pharmaceuticals to $30 From $31, Maintains Neutral Rating

MT Newswires Live
·
Jan 08

Biopharma Sector Enters 2026 With Clearer Outlook, Key Catalysts, BofA Says

MT Newswires Live
·
Jan 08

Amphastar Pharmaceuticals Senior EVP Rong Zhou Reports Disposal of Common Shares

Reuters
·
Dec 19, 2025

Director Floyd F. Petersen Reports Disposal of Amphastar Pharmaceuticals Inc. Common Shares

Reuters
·
Dec 16, 2025

Sector Update: Health Care Stocks Advance Pre-Bell Monday

MT Newswires Live
·
Dec 15, 2025

Amphastar Pharmaceuticals Says FDA Approved Teriparatide Injection as Osteoporosis Treatment

MT Newswires Live
·
Dec 15, 2025

Amphastar Pharmaceuticals: FDA Determined That Co's Teriparatide Is Bioequivalent & Therapeutically Equivalent to Eli Lilly's Forteo

THOMSON REUTERS
·
Dec 15, 2025

Amphastar Pharmaceuticals Inc: FDA Approval for Teriparatide Injection

THOMSON REUTERS
·
Dec 15, 2025

FDA Approves Amphastar's Teriparatide Prefilled Pen for Osteoporosis

Reuters
·
Dec 15, 2025

Is Amphastar Pharmaceuticals Mispriced After a Tough Year and Promising Cash Flow Outlook in 2025?

Simply Wall St.
·
Dec 10, 2025

Amphastar Pharmaceuticals Initiated at Equal-Weight by Barclays

Dow Jones
·
Dec 09, 2025